HK1210782A1 - Lfa-1 inhibitor and polymorph thereof - Google Patents
Lfa-1 inhibitor and polymorph thereof Download PDFInfo
- Publication number
- HK1210782A1 HK1210782A1 HK15111648.6A HK15111648A HK1210782A1 HK 1210782 A1 HK1210782 A1 HK 1210782A1 HK 15111648 A HK15111648 A HK 15111648A HK 1210782 A1 HK1210782 A1 HK 1210782A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- lfa
- polymorph
- inhibitor
- disclosed
- intermediates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675663P | 2012-07-25 | 2012-07-25 | |
| US61/675,663 | 2012-07-25 | ||
| US201261680099P | 2012-08-06 | 2012-08-06 | |
| US61/680,099 | 2012-08-06 | ||
| US201261729294P | 2012-11-21 | 2012-11-21 | |
| US61/729,294 | 2012-11-21 | ||
| PCT/US2013/052044 WO2014018748A1 (en) | 2012-07-25 | 2013-07-25 | Lfa-1 inhibitor and polymorph thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1210782A1 true HK1210782A1 (en) | 2016-05-06 |
Family
ID=49995472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111648.6A HK1210782A1 (en) | 2012-07-25 | 2013-07-25 | Lfa-1 inhibitor and polymorph thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9085553B2 (enExample) |
| EP (3) | EP4406950A3 (enExample) |
| JP (3) | JP6607780B2 (enExample) |
| KR (2) | KR102157608B1 (enExample) |
| CN (2) | CN104797574B (enExample) |
| AU (5) | AU2013295706A1 (enExample) |
| BR (1) | BR112015001608B1 (enExample) |
| CA (1) | CA2879982C (enExample) |
| HK (1) | HK1210782A1 (enExample) |
| IN (1) | IN2015DN00847A (enExample) |
| MX (2) | MX2015001098A (enExample) |
| RU (1) | RU2658015C2 (enExample) |
| SI (1) | SI3715345T1 (enExample) |
| WO (1) | WO2014018748A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101175488B (zh) * | 2005-05-17 | 2012-04-18 | 萨可德公司 | 治疗眼病的组合物和方法 |
| EP3632444A3 (en) * | 2008-04-15 | 2020-08-26 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| HK1210782A1 (en) | 2012-07-25 | 2016-05-06 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
| CN106714801B (zh) * | 2014-09-25 | 2021-04-06 | 诺华股份有限公司 | 连续流羧基化反应 |
| CA2973471A1 (en) | 2015-01-12 | 2016-07-21 | Kedalion Therapeutics, Inc. | Micro-droplet delivery device and methods |
| CA3016546A1 (en) | 2016-03-04 | 2017-09-08 | James M. Rynerson | Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation |
| US11013736B2 (en) * | 2016-07-29 | 2021-05-25 | Wuhan Ll Science And Technology Development Co., Ltd. | Oral solid preparation and use thereof |
| MX2019001633A (es) | 2016-08-12 | 2019-09-18 | Silk Tech Ltd | Proteina derivada de la seda para el tratamiento de la inflamacion. |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| KR102866401B1 (ko) | 2017-01-20 | 2025-10-01 | 보슈 롬 아일랜드 리미티드 | 압전 유체 분배기 |
| CN106947792A (zh) * | 2017-03-07 | 2017-07-14 | 上海倍殊生物科技有限公司 | 一种间甲砜基‑l‑苯丙氨酸的制备方法 |
| CN110831938B (zh) * | 2017-06-30 | 2023-08-01 | 台湾神隆股份有限公司 | 用于制备立他司特和其中间体的方法 |
| WO2019020580A1 (en) * | 2017-07-24 | 2019-01-31 | Interquim, S.A. | PROCESS FOR PREPARING AND PURIFYING LIFITEGRAST ANTAGONIST OF LFA-1 |
| WO2019026014A1 (en) * | 2017-08-03 | 2019-02-07 | Dr. Reddy's Laboratories Limited | METHODS FOR PREPARING LIFITEGRAST AND ITS INTERMEDIATES |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| US11246862B2 (en) | 2017-10-10 | 2022-02-15 | Mankind Pharma Ltd. | Process for the preparation of lifitegrast |
| WO2019097547A1 (en) * | 2017-11-15 | 2019-05-23 | Cipla Limited | An improved process for the preparation of lifitegrast or salts thereof |
| WO2019096996A1 (en) | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| WO2019113483A1 (en) | 2017-12-08 | 2019-06-13 | Kedalion Therapeutics, Inc. | Fluid delivery alignment system |
| US11453118B2 (en) | 2018-01-15 | 2022-09-27 | Cognibotics Ab | Industrial robot arm |
| US10435395B1 (en) | 2018-03-30 | 2019-10-08 | Scinopharm Taiwan, Ltd. | Crystal forms of lifitegrast |
| US11345683B2 (en) * | 2018-03-31 | 2022-05-31 | Aurobindo Pharma Ltd | Process for the preparation of lifitegrast |
| US20190314198A1 (en) | 2018-04-12 | 2019-10-17 | Kedalion Therapeutics, Inc. | Topical Ocular Delivery Methods and Devices for Use in the Same |
| US12350194B1 (en) | 2018-04-12 | 2025-07-08 | Bausch + Lomb Ireland Limited | Topical ocular delivery of fluids with controlled mass dosing and wireless communication |
| IT201800006337A1 (it) * | 2018-06-14 | 2019-12-14 | Procedimento per la preparazione di lifitegrast | |
| CA3102410A1 (en) | 2018-07-03 | 2020-01-09 | Kedalion Therapeutics, Inc. | Topical ocular delivery devices and methods for using the same |
| CN109384717A (zh) * | 2018-10-29 | 2019-02-26 | 广安凯特制药有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酸盐酸盐水合物及其制备方法和用途 |
| CN111100118A (zh) * | 2018-10-29 | 2020-05-05 | 重庆圣华曦药业股份有限公司 | 一种立他司特杂质及其制备方法 |
| CN111285855A (zh) * | 2018-12-07 | 2020-06-16 | 苏州旺山旺水生物医药有限公司 | 一种制备化合物Lifitegrast的方法 |
| CN111471003B (zh) * | 2019-01-24 | 2022-09-23 | 上海皓元医药股份有限公司 | 一种立他司特中间体的制备方法 |
| US12097145B2 (en) | 2019-03-06 | 2024-09-24 | Bausch + Lomb Ireland Limited | Vented multi-dose ocular fluid delivery system |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| CN114025759A (zh) * | 2019-04-18 | 2022-02-08 | 阿祖拉眼科有限公司 | 用于治疗眼病的化合物和方法 |
| CN110256343A (zh) * | 2019-05-28 | 2019-09-20 | 苏州芝宇生物科技有限公司 | 3,5-二氯-4-溴异喹啉衍生物及其制备方法和应用 |
| CN112409256B (zh) * | 2019-08-21 | 2024-04-02 | 山东福长药业有限公司 | 5,7-二氯四氢异喹啉缩醛胺类化合物、其制备方法与应用 |
| US12496218B1 (en) | 2019-11-12 | 2025-12-16 | Bausch + Lomb Ireland Limited | Fractionated topical ocular drug delivery methods and devices for use in the same |
| CN111057003A (zh) * | 2019-12-06 | 2020-04-24 | 广安凯特制药有限公司 | 一种立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉的合成方法 |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| US12290472B2 (en) | 2020-04-17 | 2025-05-06 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| WO2021212038A1 (en) | 2020-04-17 | 2021-10-21 | Kedalion Therapeutics, Inc. | Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir |
| AU2021257273A1 (en) | 2020-04-17 | 2022-11-17 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| CN111205275A (zh) * | 2020-04-22 | 2020-05-29 | 南京佰麦生物技术有限公司 | 立他司特晶型及其制备方法 |
| CN112321506B (zh) * | 2020-11-26 | 2021-12-24 | 江西天戌药业有限公司 | 一种5,7-二氯-1,2,3,4-四氢异喹啉的制备方法 |
| CN112500343B (zh) * | 2020-12-26 | 2023-04-07 | 山东金城柯瑞化学有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN112300139A (zh) * | 2020-12-29 | 2021-02-02 | 南京佰麦生物技术有限公司 | 立他司特水合物晶型及其制备方法 |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN113880819B (zh) * | 2021-09-18 | 2024-09-20 | 浙江大学医学院附属第一医院 | 立他司特的制备方法及其中间体化合物 |
| CN114524767B (zh) * | 2022-03-11 | 2022-10-18 | 成都道合尔医药技术有限公司 | 立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN115784950B (zh) * | 2022-12-08 | 2024-06-28 | 广东先强药业有限公司 | 一种立他司特中间体的制备方法 |
| CN116239532B (zh) * | 2022-12-19 | 2023-11-07 | 浙江博崤生物制药有限公司 | 一种二氯四氢异喹啉羧酸的中间体及其制备方法和应用 |
| CN116462644B (zh) * | 2023-05-06 | 2024-11-19 | 上海华默西医药科技有限公司 | 一种2-(呋喃-2-基亚甲基)-4-硝基丁酸酯化合物及其制备方法和应用 |
| WO2025186758A1 (en) * | 2024-03-08 | 2025-09-12 | Olon S.P.A. | Process for preparing lifitegrast |
| WO2025186765A1 (en) * | 2024-03-08 | 2025-09-12 | Olon S.P.A. | Process for preparing lifitegrast |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5759843A (en) * | 1980-09-30 | 1982-04-10 | Neos Co Ltd | Perfluoroalkyl ether amide derivative and its preparation |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| DE3852374T2 (de) | 1987-11-02 | 1995-05-04 | Baylor College Medicine | Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen. |
| ATE90570T1 (de) | 1988-01-29 | 1993-07-15 | Sumitomo Pharma | Verbesserte formulierungen mit kontrollierter abgabe. |
| DE3802996A1 (de) | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| ES2075016T3 (es) | 1988-08-23 | 1995-10-01 | Dana Farber Cancer Inst Inc | La subunidad alfa del receptor de adherencia a leucocitos lfa-1. |
| EP0362531B1 (en) | 1988-09-01 | 1999-11-10 | Bayer Corporation | A human rhinovirus receptor protein that inhibits virus infectivity |
| HU218904B (hu) | 1988-09-28 | 2000-12-28 | Dana-Farber Cancer Institute | Eljárás ICAM-1-et kódoló rekombináns DNS előállítására, ICAM-1-et kifejező sejtek vagy ezzel kapcsolatos betegségek diagnosztizálására és a specifikus védekező rendszer válaszából eredő gyulladások kezelésére szolgáló gyógyszerkészítmények előállítására |
| US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| EP0462184A4 (en) | 1989-03-09 | 1992-01-08 | Dana Farber Cancer Institute | Method of treating viral infections using lfa-1 |
| WO1990013316A1 (en) | 1989-04-28 | 1990-11-15 | Baylor College Of Medicine | Dissemination of hiv-1 infected cells |
| CH679207A5 (enExample) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| WO1991019511A1 (en) | 1990-06-18 | 1991-12-26 | The General Hospital Corporation | CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5318965A (en) | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| AU8631991A (en) | 1990-08-27 | 1992-03-17 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
| JP2995860B2 (ja) | 1990-11-27 | 1999-12-27 | 味の素株式会社 | 新規ペプチド |
| US5288854A (en) | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| AU2777092A (en) | 1991-10-04 | 1993-05-03 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Treatment of ocular inflammation by blockage of cell adhesion molecules |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5298492A (en) | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| AU5466794A (en) | 1992-11-18 | 1994-06-08 | Helsinki University Licensing Ltd Oy | Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| ATE236655T1 (de) | 1993-01-06 | 2003-04-15 | Kinerton Ltd | Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden |
| US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
| US5397791A (en) | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DE59409322D1 (de) | 1993-12-03 | 2000-06-08 | Hoffmann La Roche | Essigsäurederivate als Arzneimittel |
| US5470953A (en) | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| EP0762886A4 (en) | 1994-04-19 | 1999-03-31 | Univ Kansas | ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF |
| US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5510495A (en) * | 1994-09-19 | 1996-04-23 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis |
| US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0710657B1 (de) | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| DE69731623D1 (de) | 1996-04-23 | 2004-12-23 | Ipsen Mfg Ireland Ltd | Saure Polymilchsäure Polymere |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ATE342262T1 (de) | 1996-11-27 | 2006-11-15 | Bristol Myers Squibb Pharma Co | Neue integrin rezeptor antagonisten |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
| CN1191063C (zh) | 1998-03-27 | 2005-03-02 | 基因技术股份有限公司 | 治疗cd11/cd18粘附受体所介导疾病的拮抗剂 |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| HK1043545A1 (zh) | 1998-11-27 | 2002-09-20 | 高田宽治 | 用於胃肠道药物传递的口服制剂 |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| DK1140170T3 (da) | 1999-01-05 | 2006-10-23 | Univ Southern Australia | Antistoffragmenter til topisk behandling af öjensygdomme |
| WO2000044731A1 (en) | 1999-01-27 | 2000-08-03 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| ES2688273T3 (es) | 1999-03-31 | 2018-10-31 | Janssen Pharmaceutica Nv | Almidón pregelatinizado en una formulación de liberación controlada |
| WO2001001964A2 (en) | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| CZ2002333A3 (cs) | 1999-08-18 | 2002-08-14 | Societe De Conseils De Recherches Et D'application | Sloučenina 1 obsahující sloučeninu A, farmaceutický prostředek a pouľití sloučeniny A pro výrobu léčiva pro léčení chorob |
| ECSP003707A (es) | 1999-10-13 | 2002-05-23 | Novartis Ag | Diazepanes |
| US6605597B1 (en) | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6294522B1 (en) | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| NZ519222A (en) | 1999-12-14 | 2004-04-30 | Genentech Inc | TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| US7326425B2 (en) | 1999-12-31 | 2008-02-05 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| US7521061B2 (en) | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| AU784226B2 (en) | 1999-12-31 | 2006-02-23 | Rutgers, The State University | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| US20030064105A1 (en) | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| EP1296943A1 (fr) | 2000-05-05 | 2003-04-02 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) | Derives d'aminoacides et leur application a titre de medicaments |
| GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| CA2414461A1 (en) | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| JP2002030052A (ja) * | 2000-07-18 | 2002-01-29 | Tosoh Corp | ヒドロキシアミノカルボン酸、その用途、及びその製造法 |
| AU2001290272A1 (en) * | 2000-09-27 | 2002-04-08 | Asahi Glass Company, Limited | Process for producing acyl fluoride and carboxylic acid salt |
| AR030817A1 (es) | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| GB0028367D0 (en) | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| PL363962A1 (en) | 2000-11-28 | 2004-11-29 | Genentech, Inc. | Lfa-1 antagonist compounds |
| US20030008848A1 (en) | 2000-12-19 | 2003-01-09 | Fleck Roman Wolfgang | Small molecules useful in the treatment of inflammatory disease |
| CA2435415A1 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| EP1231212B1 (en) | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
| AU2002250236A1 (en) | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| WO2002074247A2 (en) | 2001-03-19 | 2002-09-26 | Praecis Pharmaceuticals Incorporated | Pharmaceutical formulations for sustained release |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| MXPA03009660A (es) | 2001-06-06 | 2004-04-02 | Aventis Pharma Ltd | Tetrahidroisoquinolinas sustituidas para su uso en el tratamiento de enfermedades inflamatorias. |
| HUP0402451A3 (en) | 2001-12-19 | 2008-04-28 | Alza Corp | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| US7943575B2 (en) | 2002-03-04 | 2011-05-17 | Ipsen Pharma S.A.S. | Sustained release drug formulations containing a carrier peptide |
| EP1542768A1 (en) | 2002-09-20 | 2005-06-22 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| US7785578B2 (en) | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| RU2005117343A (ru) * | 2002-12-20 | 2006-01-27 | Астразенека Аб (Se) | Новые производные пиперидина в качестве модуляторов хемокинового рецептора ccr5 |
| WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| WO2005042710A1 (en) | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| EP1682537B1 (en) | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
| GT200500139A (es) | 2004-06-08 | 2005-07-25 | Metodo para la preparacion de acidos hidroxamicos | |
| BRPI0610433A2 (pt) * | 2005-04-28 | 2010-11-23 | Wyeth Corp | forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada |
| CN101175488B (zh) | 2005-05-17 | 2012-04-18 | 萨可德公司 | 治疗眼病的组合物和方法 |
| WO2007057919A2 (en) * | 2005-10-25 | 2007-05-24 | Alembic Limited | An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine |
| JP4193895B2 (ja) | 2006-10-12 | 2008-12-10 | 横河電機株式会社 | 欠陥検査装置 |
| EP3167886B1 (en) | 2007-10-19 | 2020-08-05 | Novartis AG | Compositions and methods for treatment of macular edema |
| KR20100113542A (ko) * | 2008-01-01 | 2010-10-21 | 시플라 리미티드 | 보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법 |
| WO2009139817A2 (en) * | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| HK1210782A1 (en) * | 2012-07-25 | 2016-05-06 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
-
2013
- 2013-07-25 HK HK15111648.6A patent/HK1210782A1/xx unknown
- 2013-07-25 IN IN847DEN2015 patent/IN2015DN00847A/en unknown
- 2013-07-25 SI SI201332083T patent/SI3715345T1/sl unknown
- 2013-07-25 MX MX2015001098A patent/MX2015001098A/es active IP Right Grant
- 2013-07-25 WO PCT/US2013/052044 patent/WO2014018748A1/en not_active Ceased
- 2013-07-25 CN CN201380048592.8A patent/CN104797574B/zh active Active
- 2013-07-25 EP EP24169178.1A patent/EP4406950A3/en active Pending
- 2013-07-25 BR BR112015001608-1A patent/BR112015001608B1/pt active IP Right Grant
- 2013-07-25 EP EP13823367.1A patent/EP2877465A4/en not_active Withdrawn
- 2013-07-25 AU AU2013295706A patent/AU2013295706A1/en not_active Abandoned
- 2013-07-25 EP EP20153723.0A patent/EP3715345B8/en active Active
- 2013-07-25 KR KR1020157004283A patent/KR102157608B1/ko active Active
- 2013-07-25 KR KR1020207026445A patent/KR20200108932A/ko not_active Ceased
- 2013-07-25 JP JP2015524447A patent/JP6607780B2/ja active Active
- 2013-07-25 US US13/950,807 patent/US9085553B2/en active Active
- 2013-07-25 RU RU2015102926A patent/RU2658015C2/ru active
- 2013-07-25 CA CA2879982A patent/CA2879982C/en active Active
- 2013-07-25 CN CN201911035155.8A patent/CN110922393A/zh active Pending
-
2015
- 2015-01-23 MX MX2020001602A patent/MX2020001602A/es unknown
- 2015-06-23 US US14/747,745 patent/US9708303B2/en active Active
-
2017
- 2017-06-13 US US15/621,141 patent/US10214517B2/en active Active
- 2017-11-22 AU AU2017265071A patent/AU2017265071B2/en active Active
-
2018
- 2018-07-19 JP JP2018135758A patent/JP2018162313A/ja active Pending
-
2019
- 2019-01-15 US US16/247,843 patent/US10906892B2/en active Active
- 2019-07-30 AU AU2019210525A patent/AU2019210525B2/en active Active
-
2020
- 2020-06-03 JP JP2020096854A patent/JP7008750B2/ja active Active
- 2020-12-02 AU AU2020281063A patent/AU2020281063A1/en not_active Abandoned
-
2023
- 2023-07-04 AU AU2023204287A patent/AU2023204287B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1210782A1 (en) | Lfa-1 inhibitor and polymorph thereof | |
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| WO2009139817A3 (en) | Crystalline pharmaceutical and methods of preparation and use thereof | |
| EP2677888B8 (en) | Garment for the neuro-musculo-skeletal assistance | |
| WO2012138981A3 (en) | New intermediates and processes for preparing ticagrelor | |
| WO2014036219A3 (en) | Methods and compositions for treatment of a genetic condition | |
| WO2011140517A9 (en) | Methods for treating diseases of the lung | |
| EP2673286A1 (en) | Therapeutic compounds | |
| LT3400944T (lt) | Ibat inhibitoriai, skirt kepenų ligų gydymui | |
| WO2013151668A3 (en) | Modified polynucleotides for the production of secreted proteins | |
| HK1206612A1 (en) | Modified polynucleotides for the production of secreted proteins | |
| HK1202549A1 (en) | Donepezil pamoate, preparation method and its use | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| WO2011150201A3 (en) | Azolyl amide compounds and methods of use thereof | |
| WO2012103810A1 (en) | Certain chemical entities, compositions, and methods | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| WO2014125506A3 (en) | A process for the preparation of ivacaftor and its intermediates | |
| WO2012061785A3 (en) | Ice inhibiting compounds and uses thereof | |
| PL2901857T3 (pl) | Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu | |
| WO2013128379A3 (en) | Crystalline polymorphic forms of linagliptin | |
| WO2013072933A3 (en) | Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide | |
| WO2012174229A3 (en) | Methods for the synthesis and purification of deoxycholic acid | |
| WO2012154879A3 (en) | Autophagy inhibitors | |
| HK1216721A1 (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| WO2014159501A3 (en) | Processes for preparing tetrahydroisoquinolines |